cognitive cybersecurity intelligence

News and Analysis


Solvias to Perform Release Testing on CASGEVY

Solvias will provide analytical release testing services for the first genome-edited cell therapy, CASGEVY™, to treat sickle cell disease in patients aged 12 and older. The therapy has gained FDA approval and conditional approval from the EMA for severe sickle cell disease and transfusion-dependent beta thalassemia treatments.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts